Keeler R, Sato A K, Claybaugh J R, Wilson N
Department of Physiology, University of British Columbia, Vancouver, Canada.
Am J Physiol. 1991 Sep;261(3 Pt 2):R665-9. doi: 10.1152/ajpregu.1991.261.3.R665.
Isolated rat kidneys were perfused with Krebs-Henseleit-bovine serum albumin solution at a mean pressure of 99 +/- 2.6 mmHg. After control periods, arginine vasopressin (AVP) was added to the perfusate at a final calculated concentration of 25 pg/ml (2.5 x 10(-11) M). Urine and perfusate samples were collected at 15-min intervals for the following 60 min to measure kidney function and the renal clearance of immunoreactive AVP (irAVP). At 15-30 min after the addition of AVP, total renal clearance of irAVP was 1,623 +/- 190 microliters.min-1.g kidney wt-1. Glomerular filtration accounted for 35 +/- 3.0% of the total clearance, and 65 +/- 10.3% was cleared by peritubular pathways. Of the filtered irAVP, 48 +/- 4.8% was recovered in the urine. To investigate the importance of V2 receptors in the metabolism of AVP, clearance measurements were made in the presence of the V2 antagonist [d(CH2)5,D-Ile2,Ile4,Arg8]AVP (5 x 10(-9) M). Total renal clearance of irAVP was reduced by 48% to 848 +/- 79 microliters.min-1.g-1. This reduction was entirely accounted for by the complete inhibition of peritubular clearance of irAVP. In the presence of the V2 antagonist, irAVP was cleared only by filtration. The proportion of filtered AVP recovered in the urine (53 +/- 8.7%) was not significantly altered by the presence of the V2 antagonist. We conclude that a major component of the renal clearance of AVP depends on receptor-mediated uptake of AVP in the kidney cells.
将离体大鼠肾脏用Krebs-Henseleit-牛血清白蛋白溶液以99±2.6 mmHg的平均压力进行灌注。在对照期后,将精氨酸加压素(AVP)添加到灌注液中,最终计算浓度为25 pg/ml(2.5×10⁻¹¹ M)。在接下来的60分钟内,每隔15分钟收集尿液和灌注液样本,以测量肾功能和免疫反应性AVP(irAVP)的肾清除率。在添加AVP后15 - 30分钟,irAVP的总肾清除率为1623±190微升·分钟⁻¹·克肾重⁻¹。肾小球滤过占总清除率的35±3.0%,65±10.3%通过肾小管周围途径清除。在滤过的irAVP中,48±4.8%在尿液中回收。为了研究V2受体在AVP代谢中的重要性,在V2拮抗剂[d(CH₂)₅,D-Ile₂,Ile₄,Arg₈]AVP(5×10⁻⁹ M)存在的情况下进行清除率测量。irAVP的总肾清除率降低了48%,降至848±79微升·分钟⁻¹·克⁻¹。这种降低完全是由于irAVP的肾小管周围清除被完全抑制。在V2拮抗剂存在的情况下,irAVP仅通过滤过清除。V2拮抗剂的存在并未显著改变在尿液中回收的滤过AVP的比例(53±8.7%)。我们得出结论,AVP肾清除的一个主要成分取决于受体介导的AVP在肾细胞中的摄取。